Other investigators have already applied this in KRAS mutant mouse models of non-small-cell lung carcinoma and pancreatic adenocarcinoma and in mouse “co-clinical trials” [41-45]. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.